Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Determine the Safety, Pharmacokinetics, Food, and Fecal Microbiome Effects of ACX-362E Administered Orally to Healthy Subjects

Trial Profile

A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase 1 Study to Determine the Safety, Pharmacokinetics, Food, and Fecal Microbiome Effects of ACX-362E Administered Orally to Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACX 362E (Primary) ; Vancomycin
  • Indications Clostridium difficile infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Acurx Pharmaceuticals
  • Most Recent Events

    • 04 Nov 2019 According to an Acurx Pharmaceuticals media release, results from this trial will be presented at he World Antimicrobial Resistance (AMR) Congress,being held in Washington, D.C. on November 6-8, 2019.
    • 04 Nov 2019 According to an Acurx Pharmaceuticals media release, results from this trial will be presented at The 7th Annual International C. diff. Conference to be held in St. Louis, MO on November 5-6, 2019
    • 30 Oct 2019 According to an Acurx Pharmaceuticals media release, this trial was conducted at Altasciences clinical pharmacology unit in the U.S.A.Altasciences successfully completed the clinical conduct, data management, and SAS programming for ACX-362E, for the treatment of Clostridioides difficile infection (CDI), on behalf of the sponsor (Acurx Pharmaceuticals).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top